Cargando…

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

BACKGROUND: Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. OBJECTIVE: To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Xiaofu, Wang, Wei, Li, Bijun, Cheng, Bo, Lin, Kangjian, Bai, Jian, Li, Huanhui, Yang, Guosheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324167/ https://www.ncbi.nlm.nih.gov/pubmed/30621625 http://dx.doi.org/10.1186/s12885-018-5228-2

Ejemplares similares

The safety and efficacy of front-firing green-light laser endoscopic en bloc photoselective vapo-enucleation of non-muscle-invasive bladder cancer
por: Cheng, Bo, et al.
Publicado: (2017)

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
por: Lin, Jian-Zhong, et al.
Publicado: (2017)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
por: Ma, Linlin, et al.
Publicado: (2019)

Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
por: Li, Xin, et al.
Publicado: (2021)

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
por: Montagnani Marelli, Marina, et al.
Publicado: (2023)

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
por: Al Nakouzi, Nader, et al.
Publicado: (2014)

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer
por: Liu, Rui-ji, et al.
Publicado: (2021)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
por: Arichi, Naoko, et al.
Publicado: (2015)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2
por: Sun, Xin-bo, et al.
Publicado: (2021)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC
por: Schade, Amy E., et al.
Publicado: (2023)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
por: Huang, Houbao, et al.
Publicado: (2020)

Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression
por: Hu, Linyi, et al.
Publicado: (2019)

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
por: Singh, Santosh Kumar, et al.
Publicado: (2020)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines
por: Yang, Jian, et al.
Publicado: (2017)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
por: Song, Bao-feng, et al.
Publicado: (2023)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Establishment and characterization of a docetaxel-resistant human prostate cancer cell line
por: Liu, Jian, et al.
Publicado: (2020)

Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
por: Williams, Michelle M., et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r1bbgnqpbfeea2p9qi6m6um8n2